Research programme: Anti-O-acetylated-GD2 monoclonal antibodies - OGD2 Pharma

Drug Profile

Research programme: Anti-O-acetylated-GD2 monoclonal antibodies - OGD2 Pharma

Alternative Names: Anti-O-acetylated-GD2 monoclonal antibody - OGD2 Pharma; OGD 201

Latest Information Update: 06 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OGD2 Pharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 29 Nov 2016 OGD2 Pharma and University of Zurich enter research collaboration for development of OAcGD2 antibodies
  • 21 Jun 2016 OGD2 Pharma and Green Cross LabCell agree on the development of Monoclonal antibodies against OAcGD2 for the treatment of Cancer
  • 21 Jun 2016 Preclinical trials in Cancer in France (IV) prior to June 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top